ABSTRACT

Objective: This study was conducted to observe Graves’ disease with hyperthyroidism in the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. Graves’ disease was confirmed by measuring free thyroxine (FT4), thyroid-stimulating hormone (TSH), and antithyroid peroxidase (anti-TPO). TRH, T-reg FOXP3 gene polymorphism, and IL-4 were examined with an enzyme-linked immunosorbent assay method.

Methods: A cross-sectional study was conducted to observe Graves’ disease with hyperthyroidism in the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. Graves’ disease was confirmed by measuring free thyroxine (FT4), thyroid-stimulating hormone (TSH), and antithyroid peroxidase (anti-TPO). TRH, T-reg FOXP3 gene polymorphism, and IL-4 were examined with an enzyme-linked immunosorbent assay method.

Results: Twenty-five subjects with Graves’ disease included in this study with an average age of 27.48 (5.6) years. Mean Wayne index is 23.44 (1.4), mean serum FT4 level is 55.55 (17.954) pmol/l, median serum TSH levels is 0.041 (0.004–0.053) mU/l, and mean anti-TPO level is 2697.539 (479.72) pg/ml. Median serum TRH level is 92.589 (24.843–253.186) pg/ml, mean T-reg FOXP3 gene polymorphism is 0.621 (0.23) ng/ml, and mean serum IL-4 level is 19.759 (7.03) pg/ml.

Conclusion: Graves’ disease with hyperthyroidism has median serum TRH level 92.589 (24.843-253.186) pg/ml and high levels of T-reg FOXP3 gene polymorphism and IL-4.

Keywords: Thyrotropin-releasing hormone, T-regulator, Interleukin-4, Graves’ disease.

INTRODUCTION

Hyperthyroidism is the tissue response to the excessive metabolic effects of thyroid hormone. It is found in 0.8–1.3% of populations worldwide. In Indonesia, the prevalence of hyperthyroidism reaches 6.9%. Hyperthyroidism can be caused by excessive stimulation of thyroid-stimulating hormone (TSH) receptors, autonomic secretion of thyroid hormones, damage to thyroid follicles, and secretion of thyroid hormones from extrathyroidal tissues. Hyperthyroidism is mostly caused by Graves’ disease which stimulates the excessive activity of the thyroid gland through its receptors. The aspects that play a role in Graves’ disease are hormonal and immunological aspects [1-4].

The hormonal factors are TSH and thyrotropin-releasing hormone (TRH). TSH is one of the links in a complex signaling network that modulates and controls thyroid growth and function in Graves’ disease. TSH circulating in the tissues is controlled by TRH levels and the feedback effect of thyroid hormone levels on the tissues. The TRH effect is initiated by binding of peptides with G protein-coupled receptor (GPCR) on the thyrotropic plasma membrane. TRH secretion is influenced by thyroid hormones through a negative feedback mechanism in the hypothalamic-pituitary-thyroid axis [5,6].

In the immunological aspects of Graves’ disease, at a higher level, it is controlled by T-regulator (T-reg) cells. Forkhead box P3 (FOXP3) is a major regulatory factor for T-reg cells. In the next stage, the T-reg will differentiate T-helper (Th) cells, which is will produce various inflammatory cytokines, including interleukin-4 (IL-4). IL-4 stimulates isotype-secreting cells immunoglobulin G3 (IgG3-SCS) which are associated with the severity of Graves’ disease. In addition to T-reg cells, B cells have a role in humoral to produce several antibodies, one of them is antithyroid peroxidase (anti-TPO). Measuring anti-TPO can be used as a predictive marker in diagnosing patients with autoimmune thyroid disorders. [6-9].

Due to the important role of these two aspects in Graves’ disease, this study was conducted to gather the levels of both aspects in patients with Graves’ disease who have not received any hyperthyroid therapy.

METHODS

This was a cross-sectional study conducted in the Internal Medicine Department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. This study was conducted from April 2018 until July 2018. This study involved 25 patients with Graves’ disease who had not received prior treatment and admitted to the metabolic, endocrine clinic at the RSUP Dr. M. Djamil Padang. Graves’ disease was confirmed by measuring free thyroxine (FT4), TSH, and anti-TPO. Pregnant patients and Graves’ relapse were excluded. All blood samples have taken from these study participants for laboratory tests. All patients have provided signed consent. This research has received ethical approval from the Ethics Committee of the Medical Faculty of Andalas University.

Examination methods
We examined serum TRH, T-reg FOXP3 gene polymorphism, and IL-4 levels. All variables were examined with enzyme-linked immunosorbent assay techniques method (Elabscience Biotechnology).

Statistical analysis
Categorical scale data were written in frequencies and percentages, while interval data or ratio scale was written in mean (standard deviation) or median (min-max).
RESULTS

There are 25 samples in this study. Patients' age in this study ranged from 17 to 33 years old. For the study, the range of patients' ages from 17 to 33 years, with the average of age is 27.48 (5.6) years. The number of female patients in this study is more than male patients, with the percentage of women are 96% and men are 4%. In this study, only one from the men patients was attended at the study. All of the patients are Graves' disease with hyperthyroid.

Mean Wayne index is 23.44 (1.4), mean serum FT4 level is 55.55 (17.98) pmol/l, median serum TSH level is 0.041 (0.004–0.053) mU/l and mean anti-TPO level is 2697.539 (479.72) pg/ml. Median serum TRH level is 92.589 (24.843–253.186) pg/ml, mean T-reg FOXP3 gene polymorphism is 0.621 (0.23) ng/ml, and mean serum IL-4 level is 19.759 (7.03) pg/ml. Research's subject characteristics can be seen in Table 1.

DISCUSSION

There were 25 subjects with Graves' disease treatment naïve included in this study. The average age of this study is smaller than the study by Laurberg et al., which is 45 years old. Liu et al. obtained the average age of their study of 33.8 years old. The average age obtained in this study is in accordance with the Indonesian Society of Endocrinology Task Force on Thyroid Diseases which states that Graves' disease appears more frequently in the third and fourth decades. This statement also fits the basic characteristics of patients with Graves' disease in other studies in different countries [4,10,11].

In this study, there was only one male patient (4%). Molnár et al. obtained a percentage of a sample of women in the study of 86.5%. Calissendorff and Falhammar obtained all the samples as women. Voskud stated that women are more prone to suffer from autoimmune disorders. Being a woman is a greater risk factor than genetic or environmental risk factors that have been discovered to date [12-14].

Mean Wayne index is 23.44 (1.4). This indicates that the study sample was clinical hyperthyroid patients. In the study by Sabit et al., mean Wayne index is 31.6. The sensitivity of the Wayne index in diagnosing hyperthyroidism is 86.9%, while the specificity is 96.6% [15,16].

Mean serum FT4 level in this study is 55.55 (17.98) pmol/l. This serum FT4 level was higher than the study by Choi and Yoo, who obtained serum FT4 levels before the initial treatment of 48.9 (21.9) pmol/l. Molnár et al. reported lower serum FT4 levels than this study and Choi and Yoo, which was 30.86 (39.54) pmol/l [12,17].

Median serum TSH levels in this study were not much different from the mean serum TSH levels in other studies. Santos et al. conducted a study of 100 Graves' disease patients and obtained the average TSH level was 0.04 (0.1) mU/l. Azizi et al. conducted a study of 85 Graves' disease patients who were divided into 34 patients who would receive methimazole and 51 patients who would receive radioiodine therapy in Iran. In patients receiving antithyroid drugs, the serum TSH level before therapy is 0.012 (0.001) mU/l. While patients who will receive radioiodine, TSH level before therapy is 0.014 (0.001) mU/l [18,19].

Mean anti-TPO in this study is 2697.539 (479.72) pg/ml. Anti-TPO antibodies from healthy subjects did not block TPO activity or interfere with the blocking activity of anti-TPO antibodies from Graves' disease, while anti-TPO antibodies from Graves' disease can fix complement, destroy thyrocytes, and act as competitive inhibitors of enzymatic activity [20].

Median serum TRH level was higher than the average TRH level obtained by Lombardi et al. in 1978 in Italy. Lombardi et al. reported average serum TRH levels 30.8 (10.5) pg/ml in normal adult men and 33.2 (11.9) pg/ml in normal adult women. However, the study did not report serum TRH levels in patients with Graves' disease [21].

In hyperthyroid patients, the thyroid hormone is stronger in inhibiting the production of TSH in the pituitary gland than the production of TRH in the hypothalamus. Graves' disease patients with hyperthyroidism show no TRH-induced response. This concludes that increased levels of circulating thyroid hormone in the blood have a strong inhibitory effect on TSH secretion from the pituitary [19,22].

Synthesis of TRH and TSH is inhibited at the level of transcription by thyroid hormones. Thyroid hormones also inhibit post-translational modification of TSH and TSH secretion. Furthermore, the thyroid hormone also modulates TSH expression by disrupting the TRH receptor in the pituitary. Although TRH stimulates TSH synthesis and secretion, negative feedback by the thyroid hormone in the pituitary remains the most important regulator of serum TSH levels. The effect of thyroid hormone in negative feedback on the hypothalamic-pituitary-thyroid axis is mediated largely by TR. The physiological set point for the synthesis and secretion of TSH is determined by the balance between the positive input of TRH and the strong negative influence of thyroid hormone [22,23].

The mean T-reg FOXP3 gene polymorphism in this study is 0.621 (0.23) ng/ml. T-reg appears to be crucial in the pathogenesis in Graves' disease. This level is higher than normal levels. Elvira and Darwin examined Graves' disease patients and obtained a T-reg FOXP3 gene polymorphism level of 23.51 (15.7) pg/ml. T-reg has a central role in the prevention of Graves' disease development. The expression of FOXP3 is crucial for T-reg development and function in regulating the balance of the immune system [8,9].

The mean IL-4 levels in this study were found to be higher than normal levels. This level is also higher than IL-4 levels in other studies of Graves' disease. Decroli et al. conducted a study in patients with Graves' disease. They found that IL-4 level before the patient received therapy was 12.23 (5.74) pg/ml. The elevated serum cytokines of Graves' disease reflect the activation and interplay of mixed Th1 and Th2 cells [7,24-27].

Table 1: Baseline characteristics

| Characteristics (n=25) | Mean (SD) | Median (min-max) | n (%) |
|------------------------|-----------|------------------|-------|
| Average age (yo)       | 27.48 (5.6) |                  |       |
| Sex                    |            |                  |       |
| Male                   |            |                  | 1 (4) |
| Female                 |            |                  | 24 (96) |
| Wayne index            | 23.44 (1.4) |                  |       |
| FT4 (pmol/l)           | 55.55 (17.98) |                |       |
| TSH (pg/ml)            |            |                  |       |
| Anti-TPO (pg/ml)       |            |                  |       |
| TRH (mU/l)             |            | 2697.539 (479.72) |        |
| T-reg FOXP3 gene polymorphism (ng/ml) | 0.621 (0.23) | 92.589 (24.843–253.186) | |
| IL-4 (pg/ml)           |            | 19.759 (7.03)    |       |

TRH: Thyrotropin-releasing hormone, T-reg: T-regulator, IL-4: Interleukin, anti-TPO: Antithyroid peroxidase, FOXP3: Forkhead box P3
CONCLUSION
Graves’ disease with hyperthyroid has median serum TRH level 92.589 (24.843–253.186) pg/ml and high levels of T-reg FOXP3 gene polymorphism and IL-4.

ACKNOWLEDGMENT
The authors would like to thank Andalas University and Biomedic Laboratory – Medical Faculty for providing the facilities to conduct the research.

AUTHORS’ CONTRIBUTION
Decroli et al. concepted the research, provided the methods, collected the data, and authored the manuscript. Dinda Aprilia collected and analyzed the data. Dinda Aprilia collected and analyzed the data.

CONFLICTS OF INTEREST
All the authors declare that they have no conflicts of interest in publishing this article.

AUTHORS’ FUNDING
This research was funded by Andalas University (UNAND) through LPPM. This research included in Klaster Riset Penelitian Percepatan ke Guru Besar – Penelitian Dasar Unggulan (KRP2GB-PDU) UNAND 2018.

REFERENCES
1. Davies T, Laurberg P, Bahn R. Hyperthyroid disorders. In: Melmed S, Polonsky K, Larsen R, Kronenberg H, editors. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier; 2011. p. 369-415.
2. Lillevang-Johansen M, Abrahamsen B, Jorgensen H, Brix T, Hegedus L. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 2017;102:2301-9.
3. Liu J, Fu J, Xu Y, Wang G. Antithyroid drug therapy for Graves’ disease and implications for recurrence. Int J Endocrinol 2017;2017:1-9.
4. The Indonesian Society of Endocrinology. Indonesian clinical practice guidelines for hyperthyroidism. J ASEAN Fed Endocr Soc 2012;27:1-5.
5. Wang PW, Chen IY, Jou SH, His E, Liu RT, Hsieh CJ. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J 2012;1:251-8.
6. Decroli E, Elvira D, Aprilia A. The effect of thionamide to TRH, TSH, IL-4, T-reg, and anti-TPO in Graves’ disease. Indones J Pharm 2019;30:122-7.
7. Decroli E, Manaf A, Syahbuddin S. Immunologic and hormonal effects of propylthiouracil treatment using maintenance dose in Graves’ disease. Acta Med Indones 2018;46:314-9.
8. Elvira D, Darwin E. Role of pro-inflammatory and regulatory cytokines in pathogenesis of Graves’ disease in association with autoantibody thyroid and regulatory FoxP3 T-cells. Int J Med Health Sci 2017;11:69-72.
9. Elvira D. The role of T-regulatory expression in autoimmune thyroid disease and its association with thyroid antibody. J Autoimmune Disord 2016;2:19.
10. Laurberg P, Nygaard B, Andersen S, Carle A, Karmisholt J, Kerbjbjerg A, et al. Association between TSH-receptor autoimmunity, hyperthyrotemia, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves’ disease study. J Thyroid Res 2014;2014:1-6.
11. Liu X, Shi B, Li H. Valuable predictive features of relapse of Graves’ disease after antithyroid drug treatment. Ann Endocrinol 2015;76:679-83.
12. Molnar I, Szentmiklosi J, Somogyi-Vari E. Hyperthyroidism in patients with Graves’ ophthalmopathy, and thyroidal, skeletal and eye muscle specific Type 2 diabetesimmunity; role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol 2017;8:525-30.
13. Azizi F, Atale L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: Comparison with radioiodine. Eur J Endocrinol 2005;152:695-701.
14. Voskuhl R. J Endocrinol Invest 1978;1:69.
15. Schmidt F, Braunbeck T. Alterations along the hypothalamic-pituitary-thyroid-axis of the zebrafish (Danio rerio) after exposure to propylthiouracil. J Thyroid Res 2011;2011:376243.
16. Nikrodnianad A, Ortega-Carvalho TM, Shibusawa N, Hashimoto K, Liao XH, Refetoff S, et al. Dominant role of thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis. J Biol Chem 2006;281:5000-7.
17. Voskuh R. J Endocrinol Invest 1978;1:69.
18. Lombardi G, Lupoli G, Scopacasa F, Panza R, Minozzi M. Plasma immunoreactive thyrotropin releasing hormone values in normal wombors. Experientia 1978;34:25.
19. Calissendorff J, Falhammar H. Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease. Endocr Connect 2017;6:200-5.
20. Hosokii R. J Endocrinol Invest 1978;1:69.
21. Polonsky K, Larsen R, Kronenberg H, editors. Williams Textbook of Endocrinology. 13th ed. Elsevier; 2011. p. 369-415.
22. Calissendorff J, Falhammar H. Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease. Endocr Connect 2017;6:200-5.
23. Choi HS, Yoo WS. Free thyroxine, anti-thyroid stimulating hormone receptor antibody titers, and absence of goiter were associated with responsiveness to methimazole in patients with new onset Graves’ disease. Endocrinol Metab 2017;32:281-7.
24. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid 2004;14:525-30.
25. Azizi F, Atale L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: Comparison with radioiodine. Eur J Endocrinol 2005;152:695-701.
26. Frollich E, Wahl R. Thyroid Antibodies antibodies in thyroid and extra-thyroidal diseases. Front Immunol 2017;8:521.
27. Lombardi G, Lupoli G, Scopacasa F, Panza R, Minozzi M. Plasma immunoreactive thyrotropin releasing hormone values in normal wombors. Experientia 1978;34:25.
28. Schmidt F, Braunbeck T. Alterations along the hypothalamic-pituitary-thyroid-axis of the zebrafish (Danio rerio) after exposure to propylthiouracil. J Thyroid Res 2011;2011:376243.
29. Nikrodnianad A, Ortega-Carvalho TM, Shibusawa N, Hashimoto K, Liao XH, Refetoff S, et al. Dominant role of thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis. J Biol Chem 2006;281:5000-7.
30. Sarkar D, Chakraborthy A, Bhattacharya C, Singh LH, Chandra AK. Exploration of gastrologic/anthyroidal potentiality of bamboo-shoots in relation to thyrooea. Int J Pharm Pharm Sci 2017;9:7-12.
31. Saptarimi NM, Wibowo MS, Giusnadar T. Correlation study of age, disease duration, and erythrocyte sedimentation rate among the Indonesian rheumatoid arthritis patients. Int J Pharm Pharm Sci 2015;7:274-7.
32. Decroli E, Manaf A, Syahbuddin S, Waspjadi S, Dillasamola D. The role of survivin and raf-1 kinase against enhancement of pancreatic beta-cell apoptosis in patients with Type 2 diabetes mellitus. Asian J Pharm Clin Res 2018;11:344-7.
33. Santos DI, Yunita S, Paramita N, Andraini T, Kartinah NT, Bayani GF, et al. Effect of Hibiscus sabdariffa Linn on IL-6 and TNF-alpha levels in overtrained rat heart. Int J Appl Pharm 2019;11:42-5.